sisomicin has been researched along with colistin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Culebras, E; Pena, I; Picazo, JJ; RodrÃguez-Avial, C; RodrÃguez-Avial, I | 1 |
| Connolly, LE; Denervaud-Tendon, V; Krause, KM; Nordmann, P; Poirel, L | 1 |
| Bail, L; da Silva Nogueira, K; Dalmolin, TV; Ito, CAS; Martins, AF; Martins, AS; Rocha, JLL; Serio, AW; Tuon, FF | 1 |
| Alharbi, A; Alshehri, S; Eljaaly, K; Ortwine, JK; Pogue, JM | 1 |
| Connolly, LE; Daikos, GL; Dwyer, JP; Friedland, I; Jubb, AM; Krause, KM; McKinnell, JA; Serio, AW; Smith, A; Talbot, GH | 1 |
| Lin, WT; Wang, JH | 1 |
1 review(s) available for sisomicin and colistin
| Article | Year |
|---|---|
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Clinical Trials as Topic; Colistin; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Randomized Controlled Trials as Topic; Sisomicin; United States; United States Food and Drug Administration; Urinary Tract Infections | 2019 |
1 trial(s) available for sisomicin and colistin
| Article | Year |
|---|---|
Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Colistin; Creatinine; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Healthcare-Associated Pneumonia; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sample Size; Sisomicin | 2019 |
4 other study(ies) available for sisomicin and colistin
| Article | Year |
|---|---|
In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae Infections; Fosfomycin; Humans; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Serratia marcescens; Sisomicin; Thienamycins; Tigecycline | 2015 |
Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
Topics: Africa; Anti-Bacterial Agents; Bacterial Proteins; Colistin; Colombia; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Proteins; Europe; Humans; Klebsiella oxytoca; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sisomicin | 2017 |
Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenem-Resistant Enterobacteriaceae; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Sisomicin; Thienamycins | 2018 |
Plazomicin for treating complicated urinary tract infection.
Topics: Colistin; Humans; Pseudomonas aeruginosa; Sisomicin; Urinary Tract Infections | 2020 |